Table 3.
Anemia, thrombocytosis and hyperlipidemia as an adverse effect depending on the duration of treatment.
| Anemia | Elevated Platelet Count | Hyperlipidemia | ||||
|---|---|---|---|---|---|---|
| Duration of the Treatment (Months) | All Patients | No History of Anemia Prior to Sirolimus | All Patients | No History of Elevated PLT 1 Prior to Sirolimus | All Patients | No History of Hyperlipidemia Prior to Sirolimus |
| N 2 (%) | N (%) | N (%) | N (%) | N (%) | N (%) | |
| 0 | 10/21 (47.62) | 0/11 (0) | 7/21 (33.33) | 0/14 (0) | 7/18 (38.89) | 0/11 (0) |
| 0–3 | 14/20 (70) | 6/11 (54.55) | 10/20 (50) | 5/13 (38.46) | 11/18 (61.11) | 7/11 (63.64) |
| 3–6 | 7/19 (36.84) | 5/10 (50) | 8/20 (42.11) | 4/11 (36.36) | 7/16 (43.75) | 4/10 (40) |
| 6–9 | 8/14 (57.14) | 4/8 (50) | 8/14 (57.14) | 5/7 (71.43) | 7/12 (58.33) | 4/7 (57.14) |
| 9–12 | 6/10 (60) | 4/6 (66.67) | 4/11 (36.36) | 4/6 (66.67) | 5/9 (55.56) | 2/5 (40) |
| 12–18 | 7/10 (70) | 4/5 (80) | 6/10 (60) | 3/3 (100) | 7/11 (63.64) | 4/6 (66.67) |
| 18–24 | 4/9 (44.44) | 2/5 (40) | 5/9 (55.56) | 3/4 (75) | 6/8 (75) | 4/6 (66.67) |
| 24–36 | 5/8 (62.50) | 2/4 (50) | 4/7 (57.14) | 3/3 (100) | 4/7 (57.14) | 2/4 (50) |
1 PLT—platelet count. 2 N—number of patients who reported the adverse effect divided by the number of patients who were tested for the adverse effect.